AI-based Prediction Model of Difficult Tracheal Intubation Using Medical Image Parameters
Launched by MU DONG LIANG · May 20, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to predict whether patients will have a difficult time with a procedure called tracheal intubation, which is often done during anesthesia. A difficult airway can be a serious problem, so it's important to identify patients who might be at higher risk. The current methods of prediction are not very accurate, so researchers want to see if using advanced technology, specifically artificial intelligence (AI) with medical imaging like CT and MRI scans, can improve the accuracy of these predictions.
To be eligible for this study, participants must be at least 18 years old, be scheduled for surgery that requires general anesthesia with intubation, and have had a CT scan of their head and neck. They also need to agree to participate in the study. Participants will not be included if they have certain conditions that could complicate the intubation, such as severe swelling in the throat or previous surgeries in that area. This trial is not currently recruiting participants, but it aims to enhance the safety of anesthesia for future patients by better predicting who may face challenges during intubation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥18 years old;
- • 2. surgical patients undergoing general anesthesia with endotracheal intubation;
- • 3. with head and neck CT examination results
- • 4. Consent to participate in the study.
- Exclusion Criteria:
- • 1. The presence of laryngeal edema;
- • 2. The presence of airway stenosis, including internal airway stenosis (such as foreign body or tumor) or stenosis caused by external tracheal mass compression;
- • 3. tracheo-esophageal fistula;
- • 4. severe gastroesophageal reflux;
- • 5. previous upper airway surgery, such as laryngeal cancer radical surgery, snoring surgery, etc.
- • 6)participating in other research projects
About Mu Dong Liang
Mu Dong Liang is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous research and development. With a strong focus on patient-centered approaches, the organization aims to enhance healthcare outcomes by facilitating the efficient design, execution, and management of clinical trials across diverse therapeutic areas. Committed to upholding the highest standards of ethical conduct and regulatory compliance, Mu Dong Liang collaborates closely with healthcare professionals, regulatory bodies, and research institutions to ensure the integrity and success of its clinical programs. Their mission is to bring safe and effective treatments to market while prioritizing the well-being of participants and the communities they serve.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported